These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

89 related items for PubMed ID: 10774700

  • 1. Cross over placebo control trial of dilazep in beta-thalassemia/hemoglobin E patients.
    Opartkiattikul N, Sukpanichnant S, Funahara Y, Sumiyoshi A, Wanachiwanawin W, Tatsumi N, Fucharoen S.
    Southeast Asian J Trop Med Public Health; 1999 Jun; 30(2):307-10. PubMed ID: 10774700
    [Abstract] [Full Text] [Related]

  • 2. A double-blind placebo control trial of dilazep in beta-thalassemia/hemoglobin E patients.
    Opartkiattikul N, Sukpanichnant S, Wanachiwanawin W, Fucharoen S, Funahara Y, Sumiyoshi A, Imai K, Sangtawesin W, Thientadakul P.
    Southeast Asian J Trop Med Public Health; 1997 Jun; 28 Suppl 3():167-71. PubMed ID: 9640622
    [Abstract] [Full Text] [Related]

  • 3. Linear growth in homozygous beta-thalassemia and beta-thalassemia/hemoglobin E patients under different treatment regimens.
    Viprakasit V, Tanphaichitr VS, Mahasandana C, Assteerawatt A, Suwantol L, Veerakul G, Kankirawatana S, Pung-Amritt P, Suvatte V.
    J Med Assoc Thai; 2001 Jul; 84(7):929-41. PubMed ID: 11759973
    [Abstract] [Full Text] [Related]

  • 4. Increase in spontaneous platelet aggregation in beta-thalassemia/hemoglobin E disease: a consequence of splenectomy.
    Opartkiattikul N, Funahara Y, Fucharoen S, Talalak P.
    Southeast Asian J Trop Med Public Health; 1992 Jul; 23 Suppl 2():36-41. PubMed ID: 1298991
    [Abstract] [Full Text] [Related]

  • 5. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program .
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of recombinant human erythropoietin in critically ill patients admitted to a long-term acute care facility: a randomized, double-blind, placebo-controlled trial.
    Silver M, Corwin MJ, Bazan A, Gettinger A, Enny C, Corwin HL.
    Crit Care Med; 2006 Sep; 34(9):2310-6. PubMed ID: 16878035
    [Abstract] [Full Text] [Related]

  • 7. High transfusion in children with beta-thalassemia/Hb E: clinical and laboratory assessment of 18 cases.
    Torcharus K, Withayathawornwong W, Sriphaisal T, Krutvacho T, Arnutti P, Suwanasophorn C.
    Southeast Asian J Trop Med Public Health; 1993 Sep; 24 Suppl 1():96-9. PubMed ID: 7886617
    [Abstract] [Full Text] [Related]

  • 8. Serum erythropoietin levels in pediatric patients with beta-thalassemia/hemoglobin E.
    Paritpokee N, Wiwanitkit V, Bhokaisawan N, Boonchalermvichian C, Preechakas P.
    Clin Lab; 2002 Sep; 48(11-12):631-4. PubMed ID: 12465748
    [Abstract] [Full Text] [Related]

  • 9. [Thalassaemia minor: national survey of uraemic patients under substitutive treatment].
    Di Iorio BR, Aucella F, Stallone C, Bellizzi V, Thalassaemia Minor in Hemodialysis Study Group.
    G Ital Nefrol; 2002 Sep; 19(3):286-93. PubMed ID: 12195396
    [Abstract] [Full Text] [Related]

  • 10. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia.
    Palazzuoli A, Silverberg D, Iovine F, Capobianco S, Giannotti G, Calabrò A, Campagna SM, Nuti R.
    Am Heart J; 2006 Dec; 152(6):1096.e9-15. PubMed ID: 17161060
    [Abstract] [Full Text] [Related]

  • 11. A scoring system for the classification of beta-thalassemia/Hb E disease severity.
    Sripichai O, Makarasara W, Munkongdee T, Kumkhaek C, Nuchprayoon I, Chuansumrit A, Chuncharunee S, Chantrakoon N, Boonmongkol P, Winichagoon P, Fucharoen S.
    Am J Hematol; 2008 Jun; 83(6):482-4. PubMed ID: 18186524
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of prophylactic large dose of tranexamic acid in spine surgery: a prospective, randomized, double-blind, placebo-controlled study.
    Elwatidy S, Jamjoom Z, Elgamal E, Zakaria A, Turkistani A, El-Dawlatly A.
    Spine (Phila Pa 1976); 2008 Nov 15; 33(24):2577-80. PubMed ID: 19011538
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Response to hydroxyurea therapy in beta-thalassemia.
    Koren A, Levin C, Dgany O, Kransnov T, Elhasid R, Zalman L, Palmor H, Tamary H.
    Am J Hematol; 2008 May 15; 83(5):366-70. PubMed ID: 18181203
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A, Salifu MO, Lunde NM, Bansal V, Fishbane S, Dougherty FC, Beyer U, Ba16285 Study Investigators.
    Clin Ther; 2007 Apr 15; 29(4):626-39. PubMed ID: 17617286
    [Abstract] [Full Text] [Related]

  • 16. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
    Voravud N, Sriuranpong V.
    J Med Assoc Thai; 2005 May 15; 88(5):607-12. PubMed ID: 16149676
    [Abstract] [Full Text] [Related]

  • 17. Attenuation of oxidative stress-induced changes in thalassemic erythrocytes by vitamin E.
    Das N, Das Chowdhury T, Chattopadhyay A, Datta AG.
    Pol J Pharmacol; 2004 May 15; 56(1):85-96. PubMed ID: 15047982
    [Abstract] [Full Text] [Related]

  • 18. Prenatal diagnosis of beta-thalassemia/Hb E by hemoglobin typing compared to DNA analysis.
    Sirichotiyakul S, Saetung R, Sanguansermsri T.
    Hemoglobin; 2009 May 15; 33(1):17-23. PubMed ID: 19205969
    [Abstract] [Full Text] [Related]

  • 19. Hemostatic alterations in beta-thalassemia/hemoglobin E patients.
    Opartkiattikul N, Tatsumi N, Funahara Y, Shirahata A, Wongtiraporn W, Tientadakul P, Fucharoen S.
    Southeast Asian J Trop Med Public Health; 1999 May 15; 30 Suppl 3():86-9. PubMed ID: 10926266
    [Abstract] [Full Text] [Related]

  • 20. NTP Toxicology and Carcinogenesis Studies of 3,4-Dihydrocoumarin (CAS No. 119-84-6) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program .
    Natl Toxicol Program Tech Rep Ser; 1993 Sep 15; 423():1-336. PubMed ID: 12616288
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.